|
시장보고서
상품코드
2053121
원발성 담관염 치료 시장 : 치료법별, 유통 채널별, 지역별Primary Biliary Cholangitis Treatment Market By Treatment Type, By Distribution Channel, By Region |
||||||
원발성 담관염 치료 시장은 2026년에 8억 3,860만 달러로 추정되며, 2033년까지 15억 3,310만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.0%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 8억 3,860만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 9.00% | 2033년 시장 규모 예측: | 15억 3,310만 달러 |
원발성 담관염(PBC)은 간 내의 가는 담관에 영향을 미치는 만성 자가면역성 간질환입니다. 질병이 진행되면 담관 세뇨관이라는 담관에 흉터와 손상이 생겨 간 내 담즙의 흐름을 방해하고 시간이 지남에 따라 간에 손상을 입힙니다. PBC의 주요 증상으로는 피로감, 가려움증, 황달 등이 있습니다. 치료하지 않으면 PBC는 결국 간경변증과 간부전을 유발할 수 있습니다. 원발성 담관염 치료 시장은 이 질환의 발병과 진행에 관여하는 다양한 경로를 표적으로 하는 약물로 구성되어 있습니다. 우르소데옥시콜산(UDCA)은 여전히 1차 선택약이지만, 많은 환자들이 충분한 효과를 얻지 못하거나 내약성이 없는 경우가 많습니다. 이러한 미충족 수요에 대응하기 위해 오베티콜산, 피브린산 유도체와 같은 2차 선택 약물이 등장하고 있습니다.
시장 역학
원발성 담관염 치료 시장은 주로 전 세계 PBC 유병률 증가에 의해 주도되고 있습니다. 다양한 추정에 따르면, PBC의 전 세계 유병률은 100만 명당 40-400명 정도로 알려져 있습니다. 또한, 기존 치료제보다 높은 효능과 우수한 내약성을 갖춘 신규 2차 치료제의 출시도 시장 성장을 견인하고 있습니다. 그러나 신약의 높은 비용과 개발도상국에서의 PBC에 대한 낮은 인식이 시장 성장을 저해하는 요인으로 작용할 수 있습니다. 새로운 작용 기전을 가진 개발 중인 약물의 출현은 이 시장의 기업들에게 기회가 될 수 있습니다. 효과적이고 안전한 치료법에 대한 규제 당국의 승인은 난치성 환자들의 요구에 부응하는 데 도움이 될 것입니다.
본 조사의 주요 특징
- 이 조사에서는 각 부문의 잠재적인 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 기업의 주요 특징, 제품 포트폴리오, 주요 특징, 재무 성과, 전략과 같은 매개 변수를 기반으로 세계 원발성 담관염 치료 시장의 주요 기업 프로파일을 작성했습니다.
- 본 조사에서 다루고 있는 주요 기업으로는 Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc, Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, Kaken Pharmaceutical Co., Ltd. 등이 포함됩니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 "원발성 담관염 치료 세계 시장 보고서"는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 원발성 담관염 치료 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 원발성 담관염 치료 시장 : 치료 유형별, 2021-2033년
제5장 원발성 담관염 치료 시장 : 유통 채널별, 2021-2033년
제6장 원발성 담관염 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.17Primary Biliary Cholangitis Treatment Market is estimated to be valued at USD 838.6 Mn in 2026 and is expected to reach USD 1,533.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 838.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.00% | 2033 Value Projection: | USD 1,533.1 Mn |
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.
Market Dynamics
The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.
Key Features of the Study
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market.
Market Segmentation
- By Treatment Type (Revenue, USD Mn, 2021 - 2033)
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- Others (Fibrates (Tricor), etc.)
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Primary Biliary Cholangitis Treatment Market
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, S.L.
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW Biotherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Primary Billiary Cholangitis Treatment, By Treatment Type
- Market Primary Billiary Cholangitis Treatment, By Distribution Channel
- Market Primary Billiary Cholangitis Treatment, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Primary Biliary Cholangitis
- Growing Adoption of Novel Drugs
- Increasing adoption of Combination Therapy
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ursodeoxycholic Acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Obeticholic Acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (Fibrates (Tricor), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Primary Biliary Cholangitis Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Intercept Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Highlight Therapeutics, S.L.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Enanta Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NW Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GENFIT
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ironwood Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- COUR Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kaken Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
